Cubist Systematic Strategies LLC Acquires 110,682 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Cubist Systematic Strategies LLC increased its position in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 49.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 334,632 shares of the company's stock after buying an additional 110,682 shares during the period. Cubist Systematic Strategies LLC owned about 0.28% of 10x Genomics worth $4,805,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Cetera Investment Advisers boosted its stake in 10x Genomics by 22.7% in the 4th quarter. Cetera Investment Advisers now owns 19,898 shares of the company's stock worth $286,000 after purchasing an additional 3,679 shares during the period. Centiva Capital LP bought a new position in 10x Genomics during the fourth quarter worth about $302,000. Balyasny Asset Management L.P. boosted its stake in 10x Genomics by 216.5% in the 4th quarter. Balyasny Asset Management L.P. now owns 140,075 shares of the company's stock worth $2,011,000 after purchasing an additional 95,820 shares during the period. Benjamin Edwards Inc. increased its holdings in 10x Genomics by 20.0% during the fourth quarter. Benjamin Edwards Inc. now owns 69,926 shares of the company's stock worth $1,004,000 after buying an additional 11,664 shares during the last quarter. Finally, BNP Paribas Financial Markets bought a new stake in 10x Genomics in the 4th quarter valued at $9,083,000. Institutional investors own 84.68% of the company's stock.

Insider Activity at 10x Genomics

In other 10x Genomics news, CEO Serge Saxonov sold 5,092 shares of 10x Genomics stock in a transaction on Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $56,368.44. Following the completion of the transaction, the chief executive officer now directly owns 879,482 shares of the company's stock, valued at $9,735,865.74. This trade represents a 0.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Alan Mateo bought 40,000 shares of 10x Genomics stock in a transaction dated Friday, February 21st. The stock was acquired at an average price of $11.14 per share, for a total transaction of $445,600.00. Following the completion of the acquisition, the director now owns 61,691 shares in the company, valued at approximately $687,237.74. The trade was a 184.41% increase in their ownership of the stock. The disclosure for this purchase can be found here. 9.39% of the stock is owned by company insiders.

10x Genomics Trading Up 8.2%

10x Genomics stock traded up $0.72 during mid-day trading on Monday, hitting $9.49. The company had a trading volume of 4,035,743 shares, compared to its average volume of 2,329,999. 10x Genomics, Inc. has a 12 month low of $6.78 and a 12 month high of $28.25. The stock's 50 day moving average price is $8.92 and its two-hundred day moving average price is $12.50. The company has a market capitalization of $1.16 billion, a PE ratio of -6.24 and a beta of 1.94.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. Equities research analysts anticipate that 10x Genomics, Inc. will post -1.43 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on TXG. Barclays dropped their price objective on 10x Genomics from $15.00 to $12.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Canaccord Genuity Group lowered their price objective on 10x Genomics from $18.00 to $15.00 and set a "buy" rating on the stock in a research report on Monday. Stifel Nicolaus lowered their price objective on shares of 10x Genomics from $21.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, February 13th. JPMorgan Chase & Co. decreased their price target on shares of 10x Genomics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research note on Friday. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 10x Genomics in a research note on Saturday. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $17.81.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.